OKYO Pharma Limited Ordinary Shares
OKYOOKYO Pharma Limited is a biotechnology company focused on developing innovative therapies for eye diseases, particularly targeting ocular inflammation and neurodegeneration. The company leverages proprietary research to create treatments aimed at improving eye health and addressing unmet medical needs in ophthalmology.
Company News
OKYO Pharma plans to accelerate the clinical development of urcosimod, its drug candidate for treating neuropathic corneal pain, by analyzing data from an early closure of its Phase 2 trial. The company aims to meet with the FDA to discuss further development of urcosimod.
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, announced that its CEO and Executive Chairman have purchased a total of 30,000 shares of the company's ordinary shares on NASDAQ at a price of US$1.04 per share.
OKYO Pharma has dosed the first patient in a Phase 2 clinical trial of its drug candidate OK-101 to treat neuropathic corneal pain, a condition with no FDA-approved treatments. The trial is designed to evaluate the safety and efficacy of OK-101 in 48 patients with neuropathic corneal pain.
OKYO Pharma, a clinical-stage biopharmaceutical company, announced that its CEO, Dr. Gary S. Jacob, will be interviewed on Bloomberg TV. The company is developing therapies for dry eye disease and neuropathic corneal pain, with its lead candidate OK-101 showing promising results in a recent Phase 2 trial.
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, announced that Panetta Partners Limited, an entity in which the Executive Chairman has a beneficial interest, purchased 50,000 of the company's ordinary shares on NASDAQ at a price of US$1.05 per share.
